List of bibliographic references indexed by Substantia Nigra (drug effects)
Number of relevant bibliographic references: 52.
[0-20] [
0 - 20][
0 - 50][
20-40]
Ident. | Authors (with country if any) | Title |
---|
000721 (2013) |
David Dybdal [États-Unis] ; Patrick A. Forcelli ; Mark Dubach ; Michael Oppedisano ; Angela Holmes ; Ludise Malkova ; Karen Gale | Topography of dyskinesias and torticollis evoked by inhibition of substantia nigra pars reticulata. |
000905 (2013) |
Jose A. Obeso ; J. Guridi ; A. Nambu ; A R Crossman | Motor manifestations and basal ganglia output activity: the paradox continues. |
001579 (2011) |
Elisa Garbayo [Espagne] ; Eduardo Ansorena [Espagne] ; Jose Luis Lanciego [Espagne] ; María Jose Blanco-Prieto [Espagne] ; María S. Aymerich [Espagne] | Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's disease |
001E74 (2010) |
Pauline Belujon [États-Unis] ; Daniel J. Lodge [États-Unis] ; Anthony A. Grace [États-Unis] | Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment |
002784 (2008) |
C. Warren Olanow [États-Unis] | Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions |
002925 (2008) |
Mario Zappia [Italie] ; Aldo Quattrone [Italie] | Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa? |
002D65 (2007) |
Martin Köllensperger [Autriche] ; Nadia Stefanova [Autriche] ; Markus Reindl [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy |
003837 (2005) |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, Finlande] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates |
003897 (2005) |
Evžen Růži Ka [République tchèque] ; Dušan Urgošík [République tchèque] ; Robert Jech [République tchèque] ; Jan Roth [République tchèque] ; Josef Vymazal [République tchèque] ; Petr Me [République tchèque] ; Vilibald Vladyka [République tchèque] | Hemiparkinsonism and levodopa‐induced dyskinesias after focal nigral lesion |
003D76 (2004) |
Guido Alves [Norvège] ; Martin Kurz [Norvège] ; Stein A. Lie [Norvège] ; Jan P. Larsen [Norvège] | Cigarette smoking in Parkinson's disease: Influence on disease progression |
004007 (2003) |
Peter Teismann [États-Unis] ; Kim Tieu [États-Unis] ; Oren Cohen [États-Unis] ; Dong-Kug Choi [États-Unis] ; Du Chu Wu [États-Unis] ; Daniel Marks [États-Unis] ; Miquel Vila [États-Unis] ; Vernice Jackson-Lewis [États-Unis] ; Serge Przedborski [États-Unis] | Pathogenic role of glial cells in Parkinson's disease |
004038 (2003) |
Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] | Models of Parkinson's disease |
004108 (2003) |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Eleni Maratos [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
004374 (2002) |
Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France] | Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence |
004693 (2001) |
Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Féger [France] | Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain |
004745 (2001) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan |
004836 (2001) |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
004845 (2001) |
Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni] | Chronic L‐DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6‐OHDA or FeCl3 nigrostriatal lesions |
004850 (2001) |
Hélène Turmel [France] ; Andreas Hartmann [France] ; Karine Parain [France] ; Aicha Douhou [France] ; Anu Srinivasan [États-Unis] ; Yves Agid [France] ; Etienne C. Hirsch [France] | Caspase‐3 activation in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated mice |
004976 (2000) |
Donato A. Di Monte [États-Unis] ; Alison Mccormack [États-Unis, Suède] ; Giselle Petzinger [États-Unis] ; Ann Marie Janson [États-Unis, Suède] ; Maryka Quik [États-Unis] ; William J. Langston [États-Unis] | Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model |
004A02 (2000) |
Leo Verhagen Metman [États-Unis] ; Spiridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis] | Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Substantia Nigra (drug effects)"
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i \
-Sk "Substantia Nigra (drug effects)" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= indexItem
|index= KwdEn.i
|clé= Substantia Nigra (drug effects)
}}
| This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 | ![](Common/icons/LogoDilib.gif) |